Suprefact (buserelin acetate) / Sanofi 
Welcome,         Profile    Billing    Logout  
 11 Diseases   8 Trials   8 Trials   280 News 


1234»
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi, Scenesse (afamelanotide) / Clinuvel, Synarel (nafarelin) / Pfizer
    Preclinical, Journal:  Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation. (Pubmed Central) -  Nov 18, 2024   
    The model presented in this manuscript provides valuable insights into the kinetics and mechanism of drug release from PLGA-based solid implants and has demonstrated the potential for optimizing formulation design. The in vitro release model, coupled with physiologically based pharmacokinetic (PBPK) modeling, can predict the in vivo performance of implants and can be used to support bioequivalence studies in a drug development program.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Effect of the Application of PGF2? Associated With Ovulation Induction in a Fixed-Time Superovulation Programme for Precocious Nellore Heifers. (Pubmed Central) -  Oct 11, 2024   
    On day 0 (D0), all animals received intravaginal insertion of a progesterone (P4) device along with intramuscular administration of 2?mg of oestradiol benzoate, plus 200?IU of follicle-stimulating hormone in decreasing doses, with 12-h intervals between D4 and D7, in addition to 150??g of D-cloprostenol on D6 and device removal on D7. On D8, the donors received 10.5??g of buserelin acetate and the treatment group received 300??g of D-cloprostenol/PGF2?...There was no difference in the total number of embryos between the control and treatment groups (10.40?
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Hyperandrogenic eumenorrheic NON-PCOS women versus women with PCOS after the GnRH-agonist stimulation test preceded by suppression of adrenal steroidogenesis with dexamethasone. (Pubmed Central) -  Sep 23, 2024   
    It has previously been shown that around half of PCOS women exhibit a hyper-response of serum 17-hydroxy-progesterone (17-OHP) to the stimulation by GnRH-agonists, also indicated as functional ovarian hyperandrogenism (FOH)...Interestingly, treatment of women with PCOS with Dex suppression and GnRH-agonist stimulation (buserelin) highlighted the possible existence of two clusters of patients: hyper-responders (HR) and normal responders (NR)...Moreover, within women with PCOS, the HR subgroup has higher insulin levels compared to the NR subgroup, when OGTT is performed. The alteration of the glucose-insulin balance and elevation of circulating androgens were more pronounced in PCOS, thus indicating that [i.] metabolic alterations might be crucial in the onset of PCOS itself and, [ii] EuHyperA might represent a milder form of PCOS.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Prostaglandin F2? treatment does not hasten ovulation in weaned sows. (Pubmed Central) -  Jun 5, 2024   
    On d 0, every cow received a 2.0-g P4 implant; in the EB+GnRH group, cows were treated with 2.0 mg i.m. of EB and 16.8 In experiment II, weaned sows that did not express estrus signs until 72 h after weaning (0 h) were assigned to: no hormone (Control; n = 45); 10
  • ||||||||||  triptorelin / Generic mfg.
    Journal:  GnRH analogue triptorelin acetate induces ovulation in jennies during oestrus. (Pubmed Central) -  Apr 1, 2024   
    Buserelin and triptorelin-treated jennies had a 25 times higher probability to ovulate between Hours 24 and 48 than controls (p?=?.003), while there were no jenny and cycle effects on the ovulatory rate. The results of this study show how triptorelin successfully induced ovulation in jennies, like other GnRH analogues previously evaluated.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Clinical, Journal:  Pregnancy outcome in long- versus short-acting gonadotropin-releasing hormone agonist cycles in participants with normal ovarian reserve: An RCT. (Pubmed Central) -  Nov 16, 2023   
    In this randomized controlled clinical trial, 400 women were randomly assigned to 2 groups (n = 200/group): the reduced dosage of long-acting GnRH agonist group (group 1, 1.25 mg Decapeptyl) and the short-acting GnRH agonist group (group 2, 0.5 mg/day Buserelin Acetate)...No significant differences were observed in the endometrial lining, the total number of retrieved and metaphase-II oocytes, progesterone, and serum estradiol levels on human chorionic gonadotropin day, fertilization rate, and top-quality embryos between the groups...A higher percentage of ovarian hyperstimulation syndrome was observed in group 2 (p = 0.005). Due to a lower percentage of ovarian hyperstimulation syndrome in group 1 and similar assisted reproductive technology outcomes in both groups, the long protocol was found to be superior to the short protocol.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi, Depo-Estradiol (estradiol cypionate) / Pfizer
    Journal:  GnRH34 with or without estradiol cypionate in timed AI in Bos indicus beef cows. (Pubmed Central) -  Aug 21, 2023   
    Due to a lower percentage of ovarian hyperstimulation syndrome in group 1 and similar assisted reproductive technology outcomes in both groups, the long protocol was found to be superior to the short protocol. On day 9 (05:00 p.m.), all cows were given GnRH (10.5
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Suprefact (buserelin acetate) / Sanofi
    Review, Journal:  Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review. (Pubmed Central) -  Aug 13, 2023   
    Anti-androgen treatments discussed include finasteride (n=8), spironolactone (n=7), cyproterone acetate (CPA) (n=5), flutamide (n=1), leuprolide (n=1), and buserelin acetate (n=1)...Improvement in HS was also noted in case reports of patients treated with buserelin acetate, leuprolide, flutamide, and liraglutide.    Hormonal treatments for HS, especially finasteride, spironolactone, and metformin, are efficacious and safe; but large-scale randomized controlled trials are needed to determine the patient populations which would benefit from these therapies...2023;22(8):785-794. doi:10.36849/JDD.7325.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Effect of the GnRH stimulation test on canine prostatic specific esterase (CPSE). (Pubmed Central) -  Aug 7, 2023   
    CPSE secretion was increased in approximately 15% of dogs treated with either buserelin or gonadorelin. Therefore, whenever performing diagnostic testing in intact male dogs, CPSE should not be assayed on a post-GnRH serum sample.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Preclinical, Journal:  Reproductive Performance of Female Rabbits Inseminated with Extenders Supplemented with GnRH Analogue Entrapped in Chitosan-Based Nanoparticles. (Pubmed Central) -  May 27, 2023   
    Extenders containing the buserelin acetate in chitosan-dextran sulphate and chitosan-alginate nanoparticles were designed and 356 females were inseminated...However, females inseminated with both systems showed similar reproductive performance. We conclude that both nanoencapsulation systems are an efficient way of intravaginal ovulation induction, allowing a reduction in the level of the GnRH analogue normally used in seminal doses from 15-25 ?g to 4 ?g.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Trial primary completion date:  Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) -  Apr 4, 2023   
    P3,  N=192, Recruiting, 
    Consuming less resources without negatively impacting on health outcomes carries ethical and practical implications for individuals and the community, as this approach may result in overall increased healthcare access. Trial primary completion date: Dec 2021 --> Dec 2025
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Ovarian torsion in IVF patients - a case series () -  Jan 8, 2023 - Abstract #Fertility2023Fertility_404;    
    * Torsion can occur in the absence of raised inflammatory markers. * Consider elective buserelin trigger in patients at high risk of OHSS.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi, dalargin (leu-enkephalin) / Burnasyan Federal Medical & Biophysical Center
    Journal:  Development and Validation of an LC-MS/MS Method for Simultaneous Determination of Short Peptide-Based Drugs in Human Blood Plasma. (Pubmed Central) -  Nov 27, 2022   
    The linearity of the method was demonstrated within a concentration range of 0.5-20 ng/mL, with correlation coefficients between 0.998-0.999 for goserelin, buserelin, triptorelin, and octreotide, respectively. The relative standard deviation (RSD, %) values for method accuracy and precision did not exceed 20% at the lower level of quantitation (LLOQ) or 15% at other concentration levels.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
    Trial completion date:  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) -  Oct 6, 2022   
    P3,  N=1538, Active, not recruiting, 
    Administration of GnRH at day 35 after AI in animals considered at risk of low embryo survival based on PAG levels allowed a reduction in pregnancy losses and improved the pregnancy rate during low-breeding season in buffalo. Trial completion date: May 2027 --> Oct 2025
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Reproductive efficiency of sows inseminated at single dose fixed-time with refrigerated, cryopreserved and encapsulated spermatozoa. (Pubmed Central) -  Oct 5, 2022   
    Forty-two hyperprolific sows were treated with buserelin and inseminated once at a single fixed time...Results show an overall reduction on fertility using the three proposal sperm preservation techniques (69.27%, 60.00% and 78.75% for refrigerated, frozen-thawed and encapsulated AI-doses, respectively). Total number of embryonic vesicles was very similar among the three treatments, however, the number of viable vesicles was numerically different among groups and thus, embryonic viability was 79.25%, 80.0% and 87.15% for refrigerated, frozen-thawed and encapsulated AI-doses, respectively.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Mitigation of low pregnancy rate in excitable Nellore cows by administration of GnRH or P4. (Pubmed Central) -  Sep 24, 2022   
    This research aimed to determine the effect of temperament on reproductive parameters including cortisol and progesterone (P4) in Nellore cows...In total, 939 cows were subjected to timed artificial insemination (TAI) and divided into three groups: (P4LA; n = 305) 150 mg of injectable long-acting progestogen 7 days after TAI; (GnRH; n = 306), 10 μg of buserelin acetate on day 7 after TAI; control group (CG; n = 328) without hormonal treatment...No statistically significant differences were observed between gestational losses when the treatments or temperaments were compared. In conclusion, the use of GnRH or P4LA, 7 days after insemination, improves pregnancy rates in excitable animals and is a viable alternative to minimize the negative impact of stress and improve reproductive efficiency in beef cattle.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  Gilt reproductive performance in a tropical environment after oestrus synchronization and fixed-time artificial insemination. (Pubmed Central) -  Sep 24, 2022   
    Gilts in the treatment 2-FTAI group were synchronized like gilts in treatment 1-TAI group but then GnRH (10 μg of buserelin) was administered 120 h after the end of altrenogest treatment and fixed time artificial inseminated twice at 24 and 32 h after GnRH irrespective of the presence of oestrus or not...The present study indicated that fixed-time AI in gilts can be successfully performed by administration of altrenogest for 18 days, GnRH at 120 h after altrenogest withdrawal and then double fixed-time AI at 24 and 32 h after the administration of GnRH. Fertility metrics such as conception rate, farrowing rate and litter performances using this method were similar to gilts inseminated at oestrus with conventional AI.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Preclinical, Journal:  The therapeutic effects of coenzyme Q10 on surgically induced endometriosis in Sprague Dawley rats. (Pubmed Central) -  Sep 2, 2022   
    Twenty seven Sprague Dawley rats were divided into four groups; Control Group (n = 7; Endometriosis group), Reference Group (n = 6; Endometriosis + Buserelin acetate, 20 mg/kg), CoQ10 Group-I (n = 7; Endometriosis + CoQ10, 50 mg/kg) and CoQ10 Group-II (n = 7; Endometriosis + CoQ10, 100 mg/kg)...CoQ10 treatments may be possible to apply, it can contribute to science in terms of a new therapeutic treatment for endometriosis. Further studies are required to evaluate the Coenzyme Q10's effects on pain and subfertility in endometriosis.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Journal:  The Kisspeptin analogue C6 induces ovulation in jennies. (Pubmed Central) -  Jul 28, 2022   
    This study in jennies compares the endocrinological effects, ovulatory and pregnancy rates of the KP analog C6 and the GnRH analog buserelin acetate...Correlations between corpora lutea CSA and VA with serum progesterone concentration were r = 0.31, P = 0.01, r = 0.38, P = 0.01, respectively...This study suggests that stimulation of the Kp system in jennies, in contrast to findings observed in mares, induces ovulation. Further studies using higher doses and/or more animals are needed to better characterize the efficacy of C6 in jennies.